NCT06049030View on ClinicalTrials.gov

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

PHASE1UnknownINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2025

Conditions
Renal Cell Carcinoma
Interventions
DRUG

HS-10516

Oral HIF-2α inhibitor

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY